147 related articles for article (PubMed ID: 33819136)
1. The structure of CLEC-2: mechanisms of dimerization and higher-order clustering.
Martin EM; Zuidscherwoude M; Morán LA; Di Y; García A; Watson SP
Platelets; 2021 Aug; 32(6):733-743. PubMed ID: 33819136
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylation on Syk Y342 is important for both ITAM and hemITAM signaling in platelets.
Kostyak JC; Mauri B; Dangelmaier C; Vari HR; Patel A; Wright M; Reddy H; Tsygankov AY; Kunapuli SP
J Biol Chem; 2022 Aug; 298(8):102189. PubMed ID: 35753354
[TBL] [Abstract][Full Text] [Related]
3. Syk and Src family kinases regulate C-type lectin receptor 2 (CLEC-2)-mediated clustering of podoplanin and platelet adhesion to lymphatic endothelial cells.
Pollitt AY; Poulter NS; Gitz E; Navarro-Nuñez L; Wang YJ; Hughes CE; Thomas SG; Nieswandt B; Douglas MR; Owen DM; Jackson DG; Dustin ML; Watson SP
J Biol Chem; 2014 Dec; 289(52):35695-710. PubMed ID: 25368330
[TBL] [Abstract][Full Text] [Related]
4. Distinct pathways regulate Syk protein activation downstream of immune tyrosine activation motif (ITAM) and hemITAM receptors in platelets.
Manne BK; Badolia R; Dangelmaier C; Eble JA; Ellmeier W; Kahn M; Kunapuli SP
J Biol Chem; 2015 May; 290(18):11557-68. PubMed ID: 25767114
[TBL] [Abstract][Full Text] [Related]
5. The C-type lectin receptors CLEC-2 and Dectin-1, but not DC-SIGN, signal via a novel YXXL-dependent signaling cascade.
Fuller GL; Williams JA; Tomlinson MG; Eble JA; Hanna SL; Pöhlmann S; Suzuki-Inoue K; Ozaki Y; Watson SP; Pearce AC
J Biol Chem; 2007 Apr; 282(17):12397-409. PubMed ID: 17339324
[TBL] [Abstract][Full Text] [Related]
6. Syk-dependent phosphorylation of CLEC-2: a novel mechanism of hem-immunoreceptor tyrosine-based activation motif signaling.
Séverin S; Pollitt AY; Navarro-Nuñez L; Nash CA; Mourão-Sá D; Eble JA; Senis YA; Watson SP
J Biol Chem; 2011 Feb; 286(6):4107-16. PubMed ID: 21098033
[TBL] [Abstract][Full Text] [Related]
7. Critical Role for an acidic amino acid region in platelet signaling by the HemITAM (hemi-immunoreceptor tyrosine-based activation motif) containing receptor CLEC-2 (C-type lectin receptor-2).
Hughes CE; Sinha U; Pandey A; Eble JA; O'Callaghan CA; Watson SP
J Biol Chem; 2013 Feb; 288(7):5127-35. PubMed ID: 23264619
[TBL] [Abstract][Full Text] [Related]
8. CLEC-2 activates Syk through dimerization.
Hughes CE; Pollitt AY; Mori J; Eble JA; Tomlinson MG; Hartwig JH; O'Callaghan CA; Fütterer K; Watson SP
Blood; 2010 Apr; 115(14):2947-55. PubMed ID: 20154219
[TBL] [Abstract][Full Text] [Related]
9. GPVI and CLEC-2 in hemostasis and vascular integrity.
Watson SP; Herbert JM; Pollitt AY
J Thromb Haemost; 2010 Jul; 8(7):1456-67. PubMed ID: 20345705
[TBL] [Abstract][Full Text] [Related]
10. The N-terminal SH2 domain of Syk is required for (hem)ITAM, but not integrin, signaling in mouse platelets.
Hughes CE; Finney BA; Koentgen F; Lowe KL; Watson SP
Blood; 2015 Jan; 125(1):144-54. PubMed ID: 25352128
[TBL] [Abstract][Full Text] [Related]
11. Divalent nanobodies to platelet CLEC-2 can serve as agonists or antagonists.
Clark JC; Martin EM; Morán LA; Di Y; Wang X; Zuidscherwoude M; Brown HC; Kavanagh DM; Hummert J; Eble JA; Nieswandt B; Stegner D; Pollitt AY; Herten DP; Tomlinson MG; García A; Watson SP
Commun Biol; 2023 Apr; 6(1):376. PubMed ID: 37029319
[TBL] [Abstract][Full Text] [Related]
12. CLEC-2 expression is maintained on activated platelets and on platelet microparticles.
Gitz E; Pollitt AY; Gitz-Francois JJ; Alshehri O; Mori J; Montague S; Nash GB; Douglas MR; Gardiner EE; Andrews RK; Buckley CD; Harrison P; Watson SP
Blood; 2014 Oct; 124(14):2262-70. PubMed ID: 25150298
[TBL] [Abstract][Full Text] [Related]
13. Novel platelet activation receptor CLEC-2: from discovery to prospects.
Suzuki-Inoue K; Inoue O; Ozaki Y
J Thromb Haemost; 2011 Jul; 9 Suppl 1():44-55. PubMed ID: 21781241
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylation of CLEC-2 is dependent on lipid rafts, actin polymerization, secondary mediators, and Rac.
Pollitt AY; Grygielska B; Leblond B; Désiré L; Eble JA; Watson SP
Blood; 2010 Apr; 115(14):2938-46. PubMed ID: 20154214
[TBL] [Abstract][Full Text] [Related]
15. G
Badolia R; Inamdar V; Manne BK; Dangelmaier C; Eble JA; Kunapuli SP
J Biol Chem; 2017 Sep; 292(35):14516-14531. PubMed ID: 28705934
[TBL] [Abstract][Full Text] [Related]
16. Platelet immunoreceptor tyrosine-based activation motif (ITAM) and hemITAM signaling and vascular integrity in inflammation and development.
Lee RH; Bergmeier W
J Thromb Haemost; 2016 Apr; 14(4):645-54. PubMed ID: 26749528
[TBL] [Abstract][Full Text] [Related]
17. Trivalent nanobody-based ligands mediate powerful activation of GPVI, CLEC-2, and PEAR1 in human platelets whereas FcγRIIA requires a tetravalent ligand.
Martin EM; Clark JC; Montague SJ; Morán LA; Di Y; Bull LJ; Whittle L; Raka F; Buka RJ; Zafar I; Kardeby C; Slater A; Watson SP
J Thromb Haemost; 2024 Jan; 22(1):271-285. PubMed ID: 37813196
[TBL] [Abstract][Full Text] [Related]
18. Clustering extent-dependent differential signaling by CLEC-2 receptors in platelets.
Dangelmaier C; Vari HR; Wright M; Kostyak JC; Kunapuli SP
Res Pract Thromb Haemost; 2022 Mar; 6(3):e12710. PubMed ID: 35573643
[TBL] [Abstract][Full Text] [Related]
19. CLEC-2 contributes to hemostasis independently of classical hemITAM signaling in mice.
Haining EJ; Cherpokova D; Wolf K; Becker IC; Beck S; Eble JA; Stegner D; Watson SP; Nieswandt B
Blood; 2017 Nov; 130(20):2224-2228. PubMed ID: 28835437
[TBL] [Abstract][Full Text] [Related]
20. Thrombomodulation via CLEC-2 targeting.
O'Callaghan CA
Curr Opin Pharmacol; 2009 Apr; 9(2):90-5. PubMed ID: 19091630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
